TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and/or standard chemotherapies.
Checked against the public recordLast updated Jul 29, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Trishula Therapeutics, Inc.
- Interventions being studied
- Combination Product: TTX-030, budigalimab and mFOLFOX6; Combination Product: TTX-030, budigalimab and docetaxel; Combination Product: TTX-030 and mFOLFOX6; Combination Product: TTX-030 and budigalimab; Combination Product: TTX-030, budigalimab, nab-paclitaxel and gemcitabine; Combination Product: TTX-030 and pembrolizumab; Combination Product: TTX-030, nab-paclitaxel and gemcitabine; Combination Product: Budigalimab and mFOLFOX6
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Abbreviated Inclusion Criteria: 1. Age 18 years or older, is willing and able to provide informed consent 2. Histologically confirmed diagnosis of unresectable or metastatic solid tumor malignancy in selected tumor types 3. Life expectancy \> 12 weeks 4. ECOG performance status of 0-1 Abbreviated Exclusion Criteria: 1. History of allergy or hypersensitivity to study treatment components. Patients with a history of severe hypersensitivity reaction to any monoclonal antibody. 2. Use of investigational agent within 28 days prior to the first dose of study treatment and throughout the study 3. Receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy 4. History of severe autoimmune disease 5. Uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- HonorHealth Research InstituteScottsdale, Arizona
- City of Hope Medical Center Clinical Trials OfficeDuarte, California
- University of Southern CaliforniaLos Angeles, California
- Cedars-Sinai Medical CenterLos Angeles, California
- UCLA Hematology/OncologyLos Angeles, California
- Chao Family Comprehensive CC, UCIOrange, California
- UC Davis Comprehensive Cancer CenterSacramento, California
- Sylvester Comprehensive Cancer Center, University of Miami Miller School of MedicineMiami, Florida
- Ocala Oncology Center PLOcala, Florida
- Orlando Health UF Health Cancer CenterOrlando, Florida
- IACT Health - John B. Amos Cancer CenterColumbus, Georgia
- University of Chicago Medical CenterChicago, Illinois
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 29, 2025. Always confirm current availability with the study team.